Mustang Bio (MBIO) announced the pricing of a public offering of an aggregate of 2,657,807 shares of its common stock, Series C-1 warrants to

WORCESTER, Mass. - Mustang Bio , Inc. (NASDAQ:MBIO), a biopharmaceutical company engaged in the development of cell therapies for cancer treatment, has announced the pricing of a public offering expected to raise approximately $8 million.

The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be approximately $8 million. The Company intends to use the net proceeds from this offering for working capital and general corporate and other purposes.